Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies

Immunotherapy

Volumn 6, Issue 5, 2014, Pages 553-567

  Wasserman, Richard L ^a  

^a DallasAllergyImmunology   (United States)

Author keywords

Facilitated subcutaneous infusion; Hyaluronidase; IgG; Pharmacokinetics; Phase III; Primary immunodeficiency disease; Recombinant human hyaluronidase; Safety; Tolerability

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INSULIN DERIVATIVE; MORPHINE; PEGYLATED RECOMBINANT HYALURONIDASE; PLACEBO; RECOMBINANT HYALURONIDASE; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; HYALURONOGLUCOSAMINIDASE; RECOMBINANT PROTEIN;

ARTICLE; CHILL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; VOMITING; COMMON VARIABLE IMMUNODEFICIENCY; IMMUNOLOGY; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

CLINICAL TRIALS, PHASE III AS TOPIC; COMMON VARIABLE IMMUNODEFICIENCY; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULIN G; INFUSIONS, SUBCUTANEOUS; RECOMBINANT PROTEINS;

EID: 84902115697     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.34     Document Type: Article

References (65)

1. International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Notarangelo LD, Fischer A et al. Primary immunodeficiencies: 2009 update. J. Allergy Clin. Immunol. 124(6), 1161-1178 (2009).
2. Bousfiha AA, Jeddane L, Ailal F et al. Primary immunodeficiency diseases worldwide: More common than generally thought. J. Clin. Immunol. 33(1), 1-7 (2013).
3. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J. Clin. Immunol. 27(5), 497-502 (2007).
4. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: From subcutaneous to intravenous infusions and back again. J. Clin. Immunol. 32(6), 1153-1164 (2012).
5. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin. Immunol. 112(1), 1-7 (2004).
6. Bonilla FA. Intravenous immunoglobulin: Adverse reactions and management. J. Allergy Clin. Immunol. 122(6), 1238-1239 (2008).
7. Berger M, Murphy E, Riley P, Bergman GE; VIRTUE Trial Investigators. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during selftreatment with subcutaneous immunoglobulin G. South Med. J. 103(9), 856-863 (2010).
8. Daly PB, Evans JH, Kobayashi RH et al. Home-based immunoglobulin infusion therapy: Quality of life and patient health perceptions. Ann. Allergy 67(5), 504-510 (1991).
9. Gardulf A, Andersen V, Björkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet 345(8946), 365-369 (1995).
10. Gardulf A, Björvell H, Andersen V et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: The patients' experiences of subcutaneous selfinfusions and home therapy. J. Adv. Nurs. 21(5), 917-927 (1995).
11. Gardulf A, Björvell H, Gustafson R, Hammarström L, Smith CI. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin. Exp. Immunol. 92(2), 200-204 (1993).
12. Gardulf A, Nicolay U, Math D et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J. Allergy Clin. Immunol. 114(4), 936-942 (2004).
13. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch. Dis. Child. 79(1), 48-51 (1998).
14. Kittner JM, Grimbacher B, Wulff W, Jäger B, Schmidt RE. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J. Clin. Immunol. 26(4), 400-405 (2006).
15. Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J. Clin. Immunol. 26(1), 65-72 (2006).
16. Wasserman RL, Melamed I, Stein MR et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J. Allergy Clin. Immunol. 130(4), 951-957 (2012).
17. Meth MJ, Rosenthal DW, Bonagura VR. Subcutaneous immunoglobulin infusion to treat infants and toddlers with antibody deficiencies. Ann. Allergy Asthma Immunol. 105(2), 187-188 (2010).
18. Frost GI. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin. Drug Deliv. 4(4), 427-440 (2007).
19. Duran-Reynals F. The effect of extracts of certain organs from normal and immunized animals on the infecting power of vaccine virus. J. Exp. Med. 50(3), 327-340 (1929).
20. Kreil G. Hyaluronidases-A group of neglected enzymes. Protein Sci. 4(9), 1666-1669 (1995).
21. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat. Rev. Cancer 4(7), 528-539 (2004).
22. Hascall VC, Laurent T. Hyaluronan: Structure and physical properties. www.glycoforum.gr.jp/science/hyaluronan/HA01/HA01E. html
23. Toole BP. Hyaluronans. In: Proteoglycans: Structure, Biology and Molecular Interactions. Iozzo R (Ed.). Marcel Dekker, NY, USA, 61-92 (2000).
24. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 20(8), 499-508 (2001).
25. Vitrase®, prescribing information. ISTA Pharmaceuticals, CA, USA (2012).
26. Amphadase®, prescribing information. Amphastar Pharmaceuticals Inc., CA, USA (2012).
27. Hylenex®, prescribing information. Halozyme Therapeutics, Inc., CA, USA (2012).
28. Woodcock J. US FDA, Department of Health and Human Services. Follow-on protein products (26 March 2007). www.hhs.gov/asl/testify/2007/04/t20070326a. html 29 HyQvia (100 mg/ml solution for infusion for subcutaneous use) summary of product characteristics. Baxter Innovations GmbH; Vienna, Austria; 2013. www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/ 002491/ WC500143851.pdf
29. Yocum RC, Sugarman B, Vaughn D, Vick A, Brunelle R, Frost G. Pharmacokinetics and glucodynamics of an insulin analog and regular insulin injected with recombinant human hyaluronidase: Fast-Acting insulins made faster. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6-10 June 2008.
30. Silverstein SM, Greenbaum S, Stern R. Hyaluronidase in ophthalmology. J. Appl. Res. 12(1), 1-13 (2012).
31. Bookbinder LH, Hofer A, Haller MF et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control. Release 114(2), 230-241 (2006).
32. Eberhart AH, Weiler CR, Erie JC. Angioedema related to the use of hyaluronidase in cataract surgery. Am. J. Ophthalmol. 138(1), 142-143 (2004).
33. Borchard K, Puy R, Nixon R. Hyaluronidase allergy: A rare cause of periorbital inflammation. Australas. J. Dermatol. 51(1), 49-51 (2010).
34. Kim TW, Lee JH, Yoon KB, Yoon DM. Allergic reactions to hyaluronidase in pain management. A report of three cases. Korean J. Anesthesiol. 60(1), 57-59 (2011).
35. Thompson CB, Shepard HM, O'Connor PM et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 9(11), 3052-3064 (2010).
36. Kang DW, Jadin L, Nekoroski T, Drake FH, Zepeda ML. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model. Drug Deliv. Transl. Res. 2(4), 254-264 (2012).
37. Allen CH, Etzwiler LS, Miller MK et al. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics 124(5), e858-e867 (2009).
38. Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr. Med. Res. Opin. 26(2), 279-288 (2010).
39. Thomas JR, Wallace MS, Yocum RC, Vaughn DE, Haller MF, Flament J. The INFUSE-Morphine study: Use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J. Pain Symptom. Manage. 38(5), 663-672 (2009).
40. Halozyme Pipeline. www.halozyme.com/Products-And-Pipeline/Pipeline/ default. aspx
41. Knight E, Carne E, Novak B et al. Self-Administered hyaluronidase- facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency. J. Clin. Pathol. 63(9), 846-847 (2010).
42. Subcuvia 160 g/l solution for injection (human normal immunoglobulin) summary of product characteristics; Baxter AG; Vienna, Austria; 2011. www.ecomm.baxter.com/ecatalog/loadResource.do?bid=54579
43. Misbah S, Sturzenegger MH, Borte M et al. Subcutaneous immunoglobulin: Opportunities and outlook. Clin. Exp. Immunol. 158(Suppl. 1), 51-59 (2009).
44. Wasserman RL, Melamed I, Kobrynski L et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J. Clin. Immunol. 31(3), 323-331 (2011a).
45. Stein M, Wasserman RL, Melamed I et al. Tolerability/ efficacy/pharmacokinetics of facilitated-subcutaneous infusion of human immune globulin G, 10%, and recombinant human hyaluronidase in adults with primary immunodeficiency: Phase 3 study. Presented at: First International Primary Immunodeficiencies Congress. Estoril, Portugal, 7-8 November 2013.
46. Church JA, Leibl H, Stein MR et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J. Clin. Immunol. 26(4), 388-395 (2006).
47. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M; Subcutaneous IgG Study Group. Safety and efficacy of selfadministered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J. Clin. Immunol. 26(3), 265-273 (2006).
48. Wasserman RL, Irani AM, Tracy J et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin. Exp. Immunol. 161(3), 518-526 (2010).
49. Hagan JB, Fasano MB, Spector S et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J. Clin. Immunol. 30(5), 734-745 (2010).
50. US Food and Drug Administration. Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Version 1, March 2003. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM070124.pdf
51. Melamed I, Wasserman RL, Stein M et al. Long-Term tolerability and safety of facilitated-subcutaneous infusion of human immune globulin G (IgG), 10%, and recombinant human hyaluronidase (rHuPH20) (IGHy): A Phase 3 extension study in patients with primary immunodeficiencies (PIs). Presented at: American Association of Asthma, Allergy and Immunology Annual Meeting. CA, USA, 28 February-4 March 2014.
52. Schiff R, Wasserman RL, Stein M et al. Recombinant human hyaluronidase facilitates dispersion of subcutaneously administered Gammagard Liquid, enabling administration of full monthly dose in single site with improved bioavailability in immunodeficient patients. Presented at: 13th Biennial Meeting of the European Society for Immunodefiencies. 's-Hertogenbosch, The Netherlands, 16-19 October 2008.
53. Rojavin M, Landersdorfer C, Bexon M, Pfister M, Sidhu J. Switching from monthly intravenous to biweekly subcutaneous immunoglobulin: A pharmacokinetic modeling and simulation approach. Presented at: American Academy of Allergy, Asthma and Immunology Annual Meeting. TX, USA, 22-26 February 2013.
54. Bruton OC. Agammaglobulinemia. Pediatrics 9(6), 722-728 (1952).
55. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: Advantages of the subcutaneous route. BioDrugs 21(2), 105-116 (2007).
56. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: Advancements into the 21st century. Ann. Allergy Asthma Immunol. 101(2), 114-121; quiz 122-123 (2008).
57. Gustafson R, Gardulf A, Hansen S et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin. Exp. Immunol. 152(2), 274-279 (2008).
58. Gardulf A, Nicolay U, Asensio O et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-A prospective multi-national study. J. Clin. Immunol. 26(2), 177-185 (2006).
59. Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: A practical approach. Adv. Ther. 28(7), 521-533 (2011).
60. Wasserman RL, Melamed I, Nelson RP Jr et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin. Pharmacokinet. 50(6), 405-414 (2011b).
61. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-Analysis of clinical studies. Clin. Immunol. 137(1), 21-30 (2010).
62. Orange JS, Belohradsky BH, Berger M et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin. Exp. Immunol. 169(2), 172-181 (2012).
63. Jolles S, Bernatowska E, de Gracia J et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin. Immunol. 141(1), 90-102 (2011).
64. Maroto Hernando M, Soler Palacín P, Martin Nalda N, Oliveras Arenas M, Español Boren T, Figueras Nadal C. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain.] An. Pediatr. (Barc.) 70(2), 111-119 (2009).
65. Muchmore DB, Vaughn DE. Accelerating and improving the consistency of rapid-Acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J. Diabetes Sci. Technol. 6(4), 764-772 (2012).